AJUBA

Across TCGA pan-cancer cohorts, AJUBA Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AJUBA data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher AJUBA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AJUBA expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, ESCA, and COAD are the cancer types where AJUBA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.103	0.549	.001	12	view →
ESCA	OS	Median	III,IV	0.117	0.574	.001	12	view →
COAD	OS	Median	II,III,IV	0.172	0.859	<.001	12	view →
STAD	OS	Median	II,III,IV	0.251	0.659	.040	6	view →
BRCA	OS	Median	All	0.842	0.963	.033	2	view →
UCEC	DFS	Median	II,III,IV	1.000	0.445	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AJUBA–CESC (DFS)

Open the CESC breakdown →